Venetoclax–azacitidine versus azacitidine for the treatment of primary refractory or first relapsed acute myeloid leukemia. An IPC-DATAML-MSKCC retrospective study Correspondence

  

Authors:	Petit, C.; Higue, J.; Acheaibi, Z.; Gilhodes, J.; Hospital, M. A.; Devillier, R.; Bewersdorf, J.; Goldberg, A. D.; Pigneux, A.; Vey, N.; Récher, C.; Stahl, M.; Bertoli, S.; Dumas, P. Y.; Garciaz, S.
Title:	Venetoclax–azacitidine versus azacitidine for the treatment of primary refractory or first relapsed acute myeloid leukemia. An IPC-DATAML-MSKCC retrospective study
Keywords:	controlled study; leukemia; gene mutation; major clinical study; overall survival; salvage therapy; cytarabine; letter; gene; etoposide; cohort analysis; cytogenetics; retrospective study; multicenter study; allogeneic hematopoietic stem cell transplantation; anthracycline; therapy; azacitidine; acute myeloid leukemia; overall response rate; human; venetoclax; relapsed/refractory aml; first relapsed acute myeloid leukemia; primary refractory acute myeloid leukemia
Journal Title:	American Journal of Hematology
Volume:	100
Issue:	5
ISSN:	0361-8609
Publisher:	John Wiley & Sons, Inc.
Date Published:	2025-05-01
Start Page:	906
End Page:	908
Language:	English
DOI:	10.1002/ajh.27626
PUBMED:	40088036
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-105000401520&doi=10.1002%2fajh.27626&partnerID=40&md5=e76c7552e61e9697f0286915b971894e
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/224792